In 2012, Neil Daly founded Skin Analytics with a vision to create a future where no one dies of skin cancer. Having grown up in Australia, he saw first-hand how vital early skin cancer detection is, and set out to build technology that could make dermatologist-quality assessments accessible to everyone. What started as an idea has since evolved into DERM (Deep Ensemble for the Recognition of Malignancy) - the world's first autonomous AI for skin cancer detection.
Today, Skin Analytics works alongside the NHS to build world-leading skin cancer pathways using AI as a Medical Device. DERM holds the prestigious Class III CE mark and UKCA Class IIa certification, making it the only AI in dermatology authorized to make clinical decisions autonomously in the cancer space. Since partnering with the NHS in 2020, Skin Analytics has seen over 170,000 patients and caught approximately 15,500 cancers, all while helping reduce waitlists and enabling dermatologists to focus on patients who need them most. The company has also partnered with major health insurers like Bupa to bring remote skin assessment services to patients' homes.
